First emergency approvals of vaccines and antibody drugs in less than a year are great achievements of modern biotechnology in our battle against the COVID-19 pandemic, but we still have no efficient therapeutics to cure severe COVID-19. Millions of lives remain at risk until we control the pandemic, and what if we will never reach herd immunity? Waiting for others to do the job cannot be the strategy, as well as betting only on vaccines.
AAV vectors from a CDMO that cares about SMEs
BackgroundThe future of AAV vector-based therapies holds great promise if manufacturers can cope with the demand. While in-house manufacturing may be an option for some companies, partnering with a CDMO can be the best choice for others. Teaming up with a One-Stop-Shop CDMO can make it easier to achieve the project goals. There are many reasons for this.
Europe needs a strategy
Latest NewsThe threat caused by the SARS-CoV-2 virus is a global one. Therefore, we have to address the coronavirus pandemic globally, but at least on a European scale. To achieve this, we need not only a vaccination strategy but also a therapy strategy.
IZB Start-up: Exosome Diagnostics
Sponsored PublicationsExosome Diagnostics develops biofluid-based molecular diagnostic tests for use in personalized medicine and collaborates with pharmaceutical companies to develop companion diagnostics (CDx).
Modernisation of patent law – boon or bane for patentees?
BackgroundThe German Patent System has been a very patentee-friendly system, in particular for smaller patentees. Enforcement of patents has been relatively easy, affordable and fast.
AZD1222 claims 79% effecacy in pivotal US study
Latest NewsFollowing assemingly good results in a Phase III study AstraZeneca goes for Emergency Use Approval in the US.
EMA recommends to continue AZD1222 vaccinations
Latest NewsOn Tuesday, Emer Cooke had already hinted at it. Now the EMA’s PRAC committee confirmed: the benefits of AZ1222 by far outweigh the risks of the COVID-19 vaccine.
Study COVID-19 variants
ProductsThree fast-spreading new variants of SARS-CoV-2 virus have emerged in recent months: the U.K. variant B.1.1.7, the Brazil variant P.1, and the South Africa variant B.1.351.
Novel COVID antibody enters clinical testing
Latest NewsGerman CORAT Therapeutics GmbH got the greenlight for Phase Ib/II testing of COR-101, an antibody that reduced virus load in the lung by more than 99 % within three days.
A simple change delivers faster study start-up
BackgroundStudy start-up is a chaotic time. There are lots of moving parts. Lots of decisions to make and processes to establish. Lots of room for error. Mistakes can quickly derail a trial – and delays are endemic. That all represents a potential waste of time and resources – just at a moment when speed is of the essence. In many cases, the problem comes down to spreadsheets.
Don’t bet only on vaccines!
Latest NewsFirst emergency approvals of vaccines and antibody drugs in less than a year are great achievements of modern biotechnology in our battle against the COVID-19 pandemic, but we still have no efficient therapeutics to cure severe COVID-19. Millions of lives remain at risk until we control the pandemic, and what if we will never reach herd immunity? Waiting for others to do the job cannot be the strategy, as well as betting only on vaccines.